Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab

Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab

.

Saved in:

Bibliographic Details
Main Authors:	A. Pawsey, P. Mahalingam, N. Senthivel, A. Ramessur, E. Turnbull, S. Usman, R. Browne, A. Patel, A. Stewart, L. Tookman, N. Counsell, R. Miller, S. Nicum, G. Eminowicz
Format:	Article
Language:	Russian
Published:	ABV-press 2025-05-01
Series:	Опухоли женской репродуктивной системы
Subjects:	рак эндометрия ленватиниб пембролизумаб переносимость токсичность
Online Access:	https://ojrs.abvpress.ru/ojrs/article/view/1354
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit
by: L. J. Wirth, et al.
Published: (2023-03-01)

A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer
by: M. S. Brose, et al.
Published: (2022-04-01)

Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
by: M. E. Cabanillas, et al.
Published: (2020-02-01)

Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States
by: F. Worden, et al.
Published: (2025-07-01)

Comparison of speed of anti-inflammatory and analgesic effect appearance of nimesulid and diclofenac sodium tablets in gout arthritis: a randomized study
by: F. M. Kudaeva, et al.
Published: (2008-02-01)

Ингибиторы контрольных точек и классическая лимфома Ходжкина: эффективность и безопасность пембролизумаба при рецидивах и рефрактерном течении опухоли (опыт ФГБУ «НМХЦ им. Н.И. Пирогова» Минздрава России)
by: Владислав Олегович Саржевский, et al.
Published: (2021-01-01)

Фармакокинетика, безопасность и переносимость первого отечественного дженерика анагрелида в сравнении с референтным препаратом
by: С. К. Зырянов, et al.
Published: (2020-07-01)

ENDOMETRIUM RECEPTIVITY. MАRKERS OF IMPLANTATION
by: МICHEL Аbou-Abdallah, et al.
Published: (2018-09-01)

RISK FACTORS OF TREATMENT FAILURE AND RECURRENT ENDOMETRIAL HYPERPLASIA IN WOMEN OF REPRODUCTIVE AGE WITH OBESITY
by: Elena A. Shakirova, et al.
Published: (2016-03-01)

Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma
by: K. V. Menshikov, et al.
Published: (2023-01-01)

Влияние прерывания терапии ленватинибом на общую эффективность лечения у пациентов с радиойодрезистентным дифференцированным раком щитовидной железы в исследовании III фазы
by: M. Tahara, et al.
Published: (2019-04-01)

Efficacy and safety of combination therapy with lenvatinib and pembrolizumab in elderly patients with advanced endometrial cancer
by: M. V. Volkonskiy, et al.
Published: (2025-05-01)

COMPARATIVE EVALUATION OF THE COMMON TOXIC PROPERTIES OF THE ANTIBIOTIC AMOXICILLIN OF THE RUSSIAN AND IMPORTED PRODUCTION (EXPERIMENTAL HYGIENIC STUDIES)
by: Лариса Геннадьевна Горохова, et al.
Published: (2024-12-01)

Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab
by: Sahana Somasegar, et al.
Published: (2025-04-01)

Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical case
by: E. A. Khachaturyan, et al.
Published: (2025-05-01)

Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2024-01-01)

Assessment of Clinical and Diagnostic Indicators of Cardiovascular Toxicity in Patients with Non-Hodgkin’s Lymphomas in the Course of Programmatic Antitumor Therapy
by: G. R. Gimatdinova, et al.
Published: (2024-04-01)

Recommendations for evaluating the safety of medicinal products containing nanoparticles
by: R. N. Alyautdin, et al.
Published: (2018-02-01)

Ингибиторы тирозинкиназ второго поколения и их токсичность у больных в хронической фазе хронического миелолейкоза
by: Н. С. Лазорко, et al.
Published: (2015-07-01)

Эффективность и токсичность лечения больных с лимфомой Ходжкина промежуточного риска: результаты многоцентрового рандомизированного исследования
by: И. А. Крячок, et al.
Published: (2015-07-01)

Determination of acute toxicity and adverse effects of high doses of prolonged use of lithium ascorbate on Wistar rats
by: K. S. Ostrenko, et al.
Published: (2016-11-01)

Efficacy and safety of lenvatinib plus pembrolizumab in patients with endometrial cancer: data from an extended study of routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2025-03-01)

Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021-01-01)

The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia
by: A. E. Protasova, et al.
Published: (2024-11-01)

GK-2 new drug with neuroprotective properties the study of acute and chronic toxicity of the finished dosage forms
by: A. V. Sorokina, et al.
Published: (2019-02-01)

The study of the acute and chronic toxicity dipeptide mimetic of brain-derived neurotrophic factor GSB-106 finished dosage form
by: S. V. Alekseeva, et al.
Published: (2019-02-01)

Аскорбиген – модификатор токсичности рифабутина
Published: (2020-12-01)

EXPERIMENTAL STUDY OF SULPIRIDE TOXICITY AT DIFFERENT FORMS OF ITS INTAKE INTO THE BODY
by: Лариса Геннадьевна Горохова, et al.
Published: (2019-12-01)

Лечение распространенных стадий лимфомы Ходжкина: обзор литературы
by: Анна Александровна Леонтьева, et al.
Published: (2015-07-01)

Neuroprotective effect of L-cycloprolylglycine on models neuronal cells damage in vitro
by: S. V. Nikolaev, et al.
Published: (2017-07-01)

Combination of pembrolizumab and lenvatinib in second-line therapy for MSS/pMMR advanced endometrial cancer: literature review and a case report
by: A. D. Darenskaya, et al.
Published: (2024-01-01)

ОПЕРАТИВНОЕ ЛЕЧЕНИЕ БОЛЬНОЙ С ПЕРВИЧНО-МНОЖЕСТВЕННЫМ СИНХРОННЫМ РАКОМ ЖЕЛУДКА И ОБОДОЧНОЙ КИШКИ, СОЧЕТАЮЩЕГОСЯ С АНОМАЛИЕЙ ВИСЦЕРАЛЬНЫХ СОСУДОВ
Published: (2015-04-01)

Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer
by: Shao-Jing Wang, et al.
Published: (2025-03-01)

Hedgehog inhibitor in the treatment of basal cell skin cancer: case report
by: Sh. I. Musin, et al.
Published: (2021-04-01)

Study of acute toxicity of the drug Tropoxin
by: A. V. Sorokina, et al.
Published: (2017-07-01)

Легочные осложнения высокодозной химиотерапии и аутологичной трансплантации костного мозга при онкогематологических заболеваниях
by: В. О. Саржевский, et al.
Published: (2014-01-01)

Occurrence of BRCA1 and BRCA2 mutation in pancreatic cancer patients
by: A. A. Kashintsev, et al.
Published: (2016-02-01)

LUNG CANCER AND STOMACH CANCER MORBIDITY IN KEMEROVO REGION FROM 1996 TO 2015
by: Сергей Анатольевич Ларин, et al.
Published: (2017-05-01)

Hereditary colorectal cancer: genetics and screening diagnostics
by: O. I. Kit, et al.
Published: (2018-08-01)

Sustained disease control with pembrolizumab-lenvatinib in a patient with heavily pre-treated recurrent endometrial carcinoma: a case report
by: Alessia Lancianese, et al.
Published: (2025-06-01)